Skip to main content
Premium Trial:

Request an Annual Quote

Biotheranostics Settles False Claims Allegations With DOJ for $2M

NEW YORK (GenomeWeb) – The US Department of Justice said on Thursday that Biotheranostics has agreed to pay $2 million to settle allegations that the company improperly billed Medicare for molecular breast cancer tests. 

The DOJ alleged the San Diego-based company promoted and performed its Breast Cancer Index test on breast cancer patients who had not been in remission for five years and who had not been taking tamoxifen. Biotheranostics then billed the Centers for Medicare & Medicaid Services for the tests, although they were unnecessary for those patients, based on published clinical trial data and clinical practice guidelines, DOJ said.

According to Biotheranostics' website, BCI can determine a breast cancer patient's risk of recurrence beyond five years. Using the original tumor biopsy, it evaluates several genes associated with cell proliferation and the estrogen signaling pathway. The test can predict the likelihood of benefit from extended endocrine therapy, the company said.

The DOJ noted that Biotheranostics did not admit to any wrongdoing in the settlement deal. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more